Adverse reaction database has minimal information

Kondro, Wayne
July 2005
CMAJ: Canadian Medical Association Journal;7/19/2005, Vol. 173 Issue 2, p137
Academic Journal
Focuses on the limitations of the Canadian Adverse Drug Reaction Information System of Health Canada, in terms of allowing physicians or patients to determine the likely incidence of adverse drug reactions. Response of Health Canada director Heather Sutcliffe to conclusions about safety and the inappropriate use of CADRIS as a prescriptive tool; Criticisms made by consumer safety groups on CADRIS; Importance of mandatory reporting of adverse drug reactions.


Related Articles

  • Report adverse reactions to Health Canada.  // British Columbia Medical Journal;Jun2013, Vol. 55 Issue 5, p233 

    The article announces that Health Canada is asking people to report a serious or unexpected adverse reaction because of any health product.

  • Sibutramine use in contraindicated conditions continues.  // Reactions Weekly;10/20/2007, Issue 1174, p3 

    This article states that Health Canada is receiving reports of cardiovascular adverse reactions associated with sibutramine use among patients who have contraindications. Health Canada has received 65 reports of such adverse reactions between January 2001 and May 2007. 13 of these reports...

  • Keeping Tabs on Drug Reactions. O'Grady, Kathleen // Herizons;Summer2003, Vol. 17 Issue 1, p16 

    PharmaWatch and Women and Health Protection, two of Canada's top advocacy groups to keep pharmaceutical companies in check, are pressuring Health Canada to establish a more effective system for reporting and monitoring adverse drug reactions. In 2003, Health Canada established a Marketed Health...

  • Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Thiessard, Frantz; Roux, Emmanuel; Miremont-Salamé, Ghada; Fourrier-Réglat, Annie; Haramburu, Françoise; Tubert-Bitter, Pascale; Bégaud, Bernard; Miremont-Salamé, Ghada; Fourrier-Réglat, Annie; Haramburu, Françoise; Bégaud, Bernard // Drug Safety;2005, Vol. 28 Issue 8, p731 

    Background: The French pharmacovigilance system is based on a network of 31 regional centres located in teaching hospitals and coordinated by the French Medicines Agency ("Agence Française de Sécurité Sanitaire des Produits de Santé" [Afssaps]). Since 1984, they have...

  • Alemtuzumab: infection-related deaths.  // WHO Drug Information;2008, Vol. 22 Issue 4, p288 

    The article reports on the warning of Health Canada regarding the side effect of alemtuzumab, a recombinant humanized monoclonal antibody and commercially known as Mabcampath, in cancer consolidation therapy along with other chemotherapeutic and biologic agents. It discusses the results of the...

  • Lessons from cisapride.  // CMAJ: Canadian Medical Association Journal;5/01/2001, Vol. 164 Issue 9, p1269 

    Editorial. Comments on the warning system in Canada about adverse side effects of drugs. Case of cisapride, a drug prescribed for stomach disorders, which caused fatal cardiac arrhythmias; How Health Canada lagged behind the United States Food and Drug Administration (FDA) in warning...

  • Adverse reaction reporting in Canada.  // WHO Drug Information;2007, Vol. 21 Issue 3, p197 

    The article reports that Health Canada has developed two new online educational modules on adverse reaction (AR) reporting of marketed health products. It included, Health Professional Reporting of Adverse (Drug) Reactions and Reporting Side Effects from Your Medicine: What You Need to Know. It...

  • A vital link in the patient safety chain.  // WHO Drug Information;2007, Vol. 21 Issue 3, p198 

    The article discusses the conceptual framework of the Health Professional Reporting of Adverse Drug Reactions (ADR), an online education tool which is developed by Health Canada. It is inferred that its module and reporting mechanism is presented in the form of a case presentation. Description...

  • Cisapride, before and after: still waiting for ADE-reporting reform. Sibbald, Barbara // CMAJ: Canadian Medical Association Journal;11/13/2001, Vol. 165 Issue 10, p1370 

    Focuses on the efforts of Health Canada to improve the country's prescription drug monitoring system. Mention of recommendations made after an inquest into the death of a teenager from the antireflux drug cisapride; Health Canada's request for a merger of the adverse drug event reporting...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics